Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 07, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 07, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will...
Lexicon Welcomes New Guidelines for the Management of Heart Failure
April 04, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention...
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
April 02, 2022 12:15 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 02, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results of a new analysis of data from the SCORED Phase 3 clinical trial of...
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
March 21, 2022 08:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 21, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial...
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
March 17, 2022 16:14 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update
February 28, 2022 06:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today reported financial results for the three months and full-year ended December 31, 2021 and...
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
February 28, 2022 06:00 ET
|
Lexicon Pharmaceuticals, Inc.
Resubmission to Correct Recently-Identified Technical Issue Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...
Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call and Webcast on February 28, 2022
February 25, 2022 21:03 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the...
Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference
January 13, 2022 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved LX9211 neuropathic pain Phase 2 studies expected to read out in 1H 2022 THE WOODLANDS, Texas, Jan. ...
Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:05 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the 40th...